March 6, 2017 03:20 PM EST

FDA lifts its hold on vadastuximab talirine after Seattle Genetics adds new safeguards

John Carroll

Editor & Founder

A little more than two months after the FDA put a clinical hold on early-stage work of its armed antibody dubbed SGN-CD33A (vadastuximab talirine) in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA lifts its hold on vadastuximab talirine after Seattle Genetics adds new safeguards

John Carroll

Editor & Founder

Sign up to read this article for free.

A look at biotech's year of the megaround

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Roche circles back to China biotech with $80M deal for lung cancer ADC

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

FDA lifts its hold on vadas­tux­imab talirine af­ter Seat­tle Ge­net­ics adds new safe­guards

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

FDA lifts its hold on vadastuximab talirine after Seattle Genetics adds new safeguards

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Roche circles back to China biotech with $80M deal for lung cancer ADC

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval